Performance of quanti FERON-TB gold and tuberculin skin test relative to subjects' risk of exposure to tuberculosis

Clinical Infectious Diseases

Volumn 58, Issue 9, 2014, Pages 1260-1266

  Mcmullen, Sharon E ^a   Pegues, David A ^b   Shofer, Frances S ^c   Sheller, Alexandra C ^d   Wiener, Evelyn B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Healthcare Epidemiology Infection Prevention and Control   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of the Health Sciences in Philadelphia   (United States)

Author keywords

diagnostic techniques and procedures; interferon gamma release tests; latent tuberculosis; sensitivity and specificity

Indexed keywords

ADULT; ARTICLE; CLINICAL EVALUATION; COLLEGE STUDENT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOW RISK POPULATION; MALE; MEDICAL RECORD REVIEW; MYCOBACTERIUM TUBERCULOSIS TEST KIT; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; COMPARATIVE STUDY; IMMUNOLOGY; PREDICTIVE VALUE; RISK; SENSITIVITY AND SPECIFICITY; STUDENT; UNITED STATES;

ADULT; FEMALE; HUMANS; MALE; ODDS RATIO; PENNSYLVANIA; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STUDENTS; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

EID: 84898897122     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu119     Document Type: Article

References (43)

1. American College Health Association. Tuberculosis screening and targeted testing of college and university students. Available at: Http://www. acha.org/Publications/docs/ACHA-Tuberculosis-Screening-Apr2012. pdf. Accessed 23 November 2012
2. Open Doors 2012. Report on international educational exchange. Available at: Http://opendoors.iienetwork.org/. Accessed 17 July 2013
3. Mazurek G, Jereb J, Vernon A, et al. Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1-25
4. Alexander TS, Miller MB, Gilligan P. Should interferon gamma release assays become the standard method for screening patients for Mycobacterium tuberculosis infections in the United States?. J Clin Microbiol 2011; 49:2086
5. Longfield J, Margileth A, Golden S, Lazoritz S, Bohan JS, Cruess DF. Interobserver and method variability in tuberculin skin testing. Pediatr Infect Dis J 1984; 3:323-6
6. Mack U, Migliori G, Sester M, et al. LTBI: Latent tuberculosis infection or lasting immune responses to M. tuberculosis?. A TBNET consensus statement. Eur Respir J 2009; 33:956-73
7. Mancuso JD, Bernardo J, Mazurek GH. The elusive "gold" standard for detecting Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 2013; 187:122-4
8. Mazurek GH, Jereb J, LoBue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15):49-55
9. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997; 126:210-4
10. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006; 174:736-42
11. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184:590-601
12. Veeser PI, Smith PK, Handy B, Martin SR. Tuberculosis screening on a health science campus: Use of QuantiFERON-TB gold test for students and employees. J Am Coll Health 2007; 56:175-80
13. Talbot EA, Harland D, Wieland-Alter W, Burrer S, Adams LV. Specificity of the tuberculin skin test and the TSPOT.TB assay among students in a low-Tuberculosis incidence setting. J Am Coll Health 2012; 60:94
14. US Centers for Disease Control and Prevention. Core curriculum on tuberculosis: What the clinician should know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention, 2013
15. QuantiFERON-TB gold [package insert]. Cellestis Inc., Victoria, Australia. Available at: Http://www.cellestis.com/IRM/Company/ShowPage. aspx?.CPID=1171. Accessed 23 November 2012
16. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-y release as-says for tuberculosis infection: Concordance, discordance or confusion?. Clin Microbiol Infect 2011; 17:806-14
17. Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis infection. Br Med Bull 2010; 93:69-84
18. Menzies D, Pai M, Comstock G. Meta-Analysis: New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340-54
19. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008; 149:177
20. Davidow A. Interferon-gamma release assay test characteristics depend upon the prevalence of active tuberculosis. Int J Tuberc Lung Dis 2009; 13:1411-5
21. Harada N, Higuchi K, Yoshiyama T, et al. Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect 2008; 56:348-53
22. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: A database of global BCG vaccination policies and practices. PLoS Med 2011; 8:e1001012
23. Menzies D. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?. Clin Infect Dis 2000; 31(Supplement 3): S71-4
24. Wang L, Turner M, Elwood R, Schulzer M, FitzGerald J. A meta-Analysis of the effect of bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002; 57:804-9
25. Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCGvaccinated persons. Respir Res 2006; 7:77
26. Cohn D. The effect of BCG vaccination on tuberculin skin testing: Does it matter?. Am J Respir Crit Care Med 2001; 164:915-6
27. Lockman S, Tappero J, Kenyon T, Rumisha D, Huebner R, Binkin N. Tuberculin reactivity in a pediatric population with high BCG vaccination coverage. Int J Tuberc Lung Dis 1999; 3:23-30
28. Reid JK, Ward H, Marciniuk D, Hudson S, Smith P, Hoeppner V. The effect of neonatal bacille Calmette-Guérin vaccination on purified protein derivative skin test results in Canadian aboriginal children. CHEST J 2007; 131:1806-10
29. Chan P, Chang L, Wu Y, et al. Age-specific cut-offs for the tuberculin skin test to detect latent tuberculosis in BCG-vaccinated children. Int J Tuberc Lung Dis 2008; 12:1401-6
30. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: What is the absolute effect of BCG and non-Tuberculous mycobacteria?. [review article]. Int J Tuberc Lung Dis 2006; 10:1192-204
31. Yeh Y, Luh D, Chang S, Suo J, Chang H, Chen T. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guérin vaccination in Taiwan. Trans R Soc Trop Med Hyg 2005; 99:509-16
32. Gandra S, Scott WS, Somaraju V, Wang H, Suzanne Wilton A, Feigenbaum M. Questionable effectiveness of the QuantiFERON-TB Gold test (Cellestis) as a screening tool in healthcare workers. Infect Control Hosp Epidemiol 2010; 31:1279-85
33. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB Gold in-Tube assay. Clin Vaccine Immunol 2008; 15:425
34. Schablon A, Harling M, Diel R, Ringshausen FC, Costa JT, Nienhaus A. Serial testing with an interferon-γ release assay in German healthcare workers. GMS Krankenhaushygiene interdisziplinär 2010; 5(2
35. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: A systematic review. Thorax 2012; 67:62-70
36. Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 2012; 185:427-34
37. Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-γ release assay conversions in serial testing of health-care workers in a TB control program: Challenge of interferon-03B3 release assay conversion. CHEST J 2012; 142:55-62
38. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: The QuantiFERON-TB gold IGRA alone is more costeffective for immigrants from high burden countries. Thorax 2010; 65:178-80
39. Wrighton-Smith P, Zellweger J. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006; 28:45-50
40. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Costeffectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009; 169:179
41. Pooran A, Booth H, Miller R, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: A cost effectiveness analysis. BMC Pulm Med 2010; 10:7
42. Nienhaus A, Schablon A, Costa J, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011; 11:247
43. Mancuso J, Niebuhr D, Frick K, Keep L, Anderson K. Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis. Int J Tuberc Lung Dis 2011; 15:1223-30.